IG Mackenzie Global Health Care Cl U (IGI1402)
25.55
+0.38 (+1.52%)
CAD |
May 20 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.25% | 317.46M | 0.51% | 74.60% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -14.37M | 12.10% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Class aims to provide long-term capital growth by investing in the common shares of global corporations engaged in the development, production or distribution of products and services related to the treatment or prevention of medical diseases or other medical related problems. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | IGI262 |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl Mkts GR CAD |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Investors Group Inc |
| Prospectus Benchmark Index | |
| MSCI World (Net) CAD Benchmark | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Eric Ng | 0.75 yrs |
| Lawrence(Larry) Llaguno | 0.75 yrs |
| ZiJian (Richard) Zhu | 0.75 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
87
-14.37M
-338.90M
Category Low
449.74M
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Johnson & Johnson | 6.95% | 179.47 | 1.41% |
| UnitedHealth Group Inc | 6.23% | 492.09 | 1.31% |
| AbbVie Inc | 4.84% | 148.01 | -1.99% |
| Pfizer Inc | 4.47% | 52.86 | 0.74% |
|
Roche Holding AG
|
4.10% | -- | -- |
| Abbott Laboratories | 3.88% | 115.10 | 1.64% |
| Thermo Fisher Scientific Inc | 3.78% | 555.33 | 0.03% |
| Merck & Co Inc | 2.89% | 93.85 | 0.32% |
| Amgen Inc | 2.88% | 248.97 | 0.59% |
| Anthem Inc | 2.61% | 494.62 | 0.36% |
Basic Info
| Investment Strategy | |
| The Class aims to provide long-term capital growth by investing in the common shares of global corporations engaged in the development, production or distribution of products and services related to the treatment or prevention of medical diseases or other medical related problems. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | IGI262 |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl Mkts GR CAD |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Investors Group Inc |
| Prospectus Benchmark Index | |
| MSCI World (Net) CAD Benchmark | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Eric Ng | 0.75 yrs |
| Lawrence(Larry) Llaguno | 0.75 yrs |
| ZiJian (Richard) Zhu | 0.75 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-20-22) | 0.51% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 19.73 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of February 28, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 7/12/2013 |
| Last Annual Report Date | 3/31/2021 |
| Last Prospectus Date | -- |
| Share Classes | |
| IGI1122 | Commission-based Advice |
| IGI1123 | Commission-based Advice |
| IGI262 | Commission-based Advice |
| IGI263 | Commission-based Advice |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |